NL2025294B1 - Antimicrobial peptide for treatment and controlling virus infections - Google Patents
Antimicrobial peptide for treatment and controlling virus infections Download PDFInfo
- Publication number
- NL2025294B1 NL2025294B1 NL2025294A NL2025294A NL2025294B1 NL 2025294 B1 NL2025294 B1 NL 2025294B1 NL 2025294 A NL2025294 A NL 2025294A NL 2025294 A NL2025294 A NL 2025294A NL 2025294 B1 NL2025294 B1 NL 2025294B1
- Authority
- NL
- Netherlands
- Prior art keywords
- seq
- antimicrobial peptide
- peptide
- virus
- amino acid
- Prior art date
Links
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims abstract description 54
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims abstract description 54
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 53
- 230000009385 viral infection Effects 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 21
- 241000282414 Homo sapiens Species 0.000 claims abstract description 18
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 208000036142 Viral infection Diseases 0.000 claims abstract description 8
- 239000003085 diluting agent Substances 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 241000700605 Viruses Species 0.000 abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 150000001413 amino acids Chemical group 0.000 description 39
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000007363 ring formation reaction Methods 0.000 description 10
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108010068380 arginylarginine Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 241000233866 Fungi Species 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 5
- -1 aromatic amino acid Chemical class 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 102000050459 human LTF Human genes 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- ZRGNRZLDMUACOW-HERUPUMHSA-N Ala-Cys-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N ZRGNRZLDMUACOW-HERUPUMHSA-N 0.000 description 4
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 4
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 4
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010058874 Viraemia Diseases 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 108010004073 cysteinylcysteine Proteins 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- JISIQDCOHJOOPU-WFBYXXMGSA-N Trp-Cys-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O JISIQDCOHJOOPU-WFBYXXMGSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 2
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- HQZGVYJBRSISDT-BQBZGAKWSA-N Cys-Gly-Arg Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQZGVYJBRSISDT-BQBZGAKWSA-N 0.000 description 2
- 206010012504 Dermatophytosis Diseases 0.000 description 2
- YADSXULAFMJZRL-QEJZJMRPSA-N Gln-Trp-Cys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N YADSXULAFMJZRL-QEJZJMRPSA-N 0.000 description 2
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- 241001460074 Microsporum distortum Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- OXVPMZVGCAPFIG-BQFCYCMXSA-N Val-Gln-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N OXVPMZVGCAPFIG-BQFCYCMXSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- UKVGHFORADMBEN-GUBZILKMSA-N Cys-Arg-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UKVGHFORADMBEN-GUBZILKMSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (3)
- CONCLUSIES: I. Antimicrobieel peptide voor gebruik in een methode voor het voorkomen of behandelen en / of beheersen van een virusinfectie bij een mens of dier, waarbij het antimicrobiële peptide een van de volgende aminozuursequenties omvat of daaruit bestaat: RRRRSVQWCA [SEQ ID NO: 1], GRRRRSVQWCA [SEQ ID NO: 3}, ACWQVSRRRR [SEQ ID NO: 2], ACWQVSRRRRG [SEQ ID NO: 4}, CGRRRRSVQWCA [SEQ ID NO: 5], of een functionele mutant daarvan,
- 2. Samenstelling omvattende een antimicrobieel peptide en een farmaceutisch aanvaardbaar verdunningsmiddel of excipiëns, voor gebruik in een methode voor het voorkomen of behandelen en / of beheersen van een virusinfectie bij een mens of dier, waarbij het antimicrobiële peptide een van de volgende aminozuursequenties omvat of daaruit bestaat: RRRRSVQWCA {SEQ ID NO: 1], GRRRRSVQWCA [SEQ ID NO: 3], ACWQVSRRRR {SEQ ID NO: 2], ACWQVSRRRRG [SEQ ID NO: 4], CGRRRRSVQWCA [SEQ ID NO: 5], of een functionele mutant daarvan.
- 3. Werkwijze voor het behandelen van een patiënt die aan virusinfecties lijdt, waarbij de methode omvat het toedienen van een therapeutisch effectieve hoeveelheid van een antimicrobieel peptide aan patiënten die zijn aangetast door virusinfecties, waarbij het antimicrobiële peptide een van de aminozuursequenties omvat of hieruit bestaat: RRRRSVQWCA [SEQ ID] NO: 1], GRRRRSVQWCA [SEQ ID NO: 3], ACWQVSRRRR [SEQ ID NO: 2}, ACWQVSRRRRG {SEQ ID NO: 4}, CGRRRRSVQWCA [SEQ ID NO: 5}, of een functionele mutant daarvan.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025294A NL2025294B1 (en) | 2020-04-07 | 2020-04-07 | Antimicrobial peptide for treatment and controlling virus infections |
| PCT/NL2021/050224 WO2021206548A1 (en) | 2020-04-07 | 2021-04-06 | Antimicrobial peptide for treatment and controlling virus infections |
| NL2027924A NL2027924B1 (en) | 2020-04-07 | 2021-04-06 | Antimicrobial peptide for prevention and treatment of virusinfections |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025294A NL2025294B1 (en) | 2020-04-07 | 2020-04-07 | Antimicrobial peptide for treatment and controlling virus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2025294B1 true NL2025294B1 (en) | 2021-10-25 |
Family
ID=73699370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2025294A NL2025294B1 (en) | 2020-04-07 | 2020-04-07 | Antimicrobial peptide for treatment and controlling virus infections |
| NL2027924A NL2027924B1 (en) | 2020-04-07 | 2021-04-06 | Antimicrobial peptide for prevention and treatment of virusinfections |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2027924A NL2027924B1 (en) | 2020-04-07 | 2021-04-06 | Antimicrobial peptide for prevention and treatment of virusinfections |
Country Status (2)
| Country | Link |
|---|---|
| NL (2) | NL2025294B1 (nl) |
| WO (1) | WO2021206548A1 (nl) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0769915A (ja) * | 1993-09-02 | 1995-03-14 | Snow Brand Milk Prod Co Ltd | ウィルス感染・増殖抑制剤 |
| EP2030980A1 (en) * | 2007-08-28 | 2009-03-04 | AM-Pharma B.V. | Mutants of lactoferrin |
| US20090142298A1 (en) * | 2007-09-05 | 2009-06-04 | Shatunovskiy Nikolay E | Apolactoferrin Compositions and Methods for Their Use in the Treatment of Viral Hepatitis C |
-
2020
- 2020-04-07 NL NL2025294A patent/NL2025294B1/en not_active IP Right Cessation
-
2021
- 2021-04-06 WO PCT/NL2021/050224 patent/WO2021206548A1/en active Application Filing
- 2021-04-06 NL NL2027924A patent/NL2027924B1/en active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0769915A (ja) * | 1993-09-02 | 1995-03-14 | Snow Brand Milk Prod Co Ltd | ウィルス感染・増殖抑制剤 |
| EP2030980A1 (en) * | 2007-08-28 | 2009-03-04 | AM-Pharma B.V. | Mutants of lactoferrin |
| WO2009028943A1 (en) | 2007-08-28 | 2009-03-05 | Am-Pharma B.V. | Mutants of lactoferrin |
| US20090142298A1 (en) * | 2007-09-05 | 2009-06-04 | Shatunovskiy Nikolay E | Apolactoferrin Compositions and Methods for Their Use in the Treatment of Viral Hepatitis C |
Non-Patent Citations (3)
| Title |
|---|
| ALLAIRE ANDRÉA ET AL: "Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus", JOURNAL OF VISUALIZED EXPERIMENTS, no. 104, 1 January 2015 (2015-01-01), XP055781354, DOI: 10.3791/53053 * |
| JENSSEN H ET AL: "Antimicrobial properties of lactoferrin", BIOCHIMIE, MASSON, PARIS, FR, vol. 91, no. 1, 1 January 2009 (2009-01-01), pages 19 - 29, XP025869223, ISSN: 0300-9084, [retrieved on 20080605], DOI: 10.1016/J.BIOCHI.2008.05.015 * |
| JENSSEN H: "Anti herpes simplex virus activity of lactoferrin/lactoferricin - an example of antiviral activity of antimicrobial protein/peptide", CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 62, no. 24, 1 December 2005 (2005-12-01), pages 3002 - 3013, XP019200911, ISSN: 1420-9071, DOI: 10.1007/S00018-005-5228-7 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021206548A1 (en) | 2021-10-14 |
| NL2027924A (en) | 2021-10-25 |
| NL2027924B1 (en) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6887847B2 (en) | Virus derived antimicrobial peptides | |
| US6835713B2 (en) | Virus derived antimicrobial peptides | |
| US7745390B2 (en) | Antimicrobial peptides | |
| BR0214188A (pt) | Anticorpos monoclonais contra vìrus da hepatite e ou seus fragmentos com atividade de ligação e uso dos mesmos | |
| AU2015336933B2 (en) | A method of treatment | |
| CN110740745A (zh) | 含有谷胱甘肽二硫化物和谷胱甘肽二硫化物s-氧化物的药物组合物 | |
| US10413586B2 (en) | Antiviral agent comprising recombinant mistletoe lectins | |
| KR20180037185A (ko) | 광범위의 항감염성 펩티드 | |
| CN112552379A (zh) | 合成肽在制备防治新型冠状病毒感染药物中的用途 | |
| US20030036627A1 (en) | Virus derived antimicrobial peptides | |
| NL2025294B1 (en) | Antimicrobial peptide for treatment and controlling virus infections | |
| KR102393872B1 (ko) | 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도 | |
| EP1075270B1 (en) | Short peptide for treatment of neurological degenerative diseases | |
| Avram et al. | Evaluation of the therapeutic properties of mastoparan-and sifuvirtide-derivative antimicrobial peptides using chemical structure-function relationship-in vivo and in silico approaches | |
| Docherty et al. | Inactivation of herpes simplex virus types 1 and 2 by synthetic histidine peptides | |
| JP3770624B2 (ja) | ウィルス感染・増殖抑制剤 | |
| SK29795A3 (en) | Inhibition of retrovirus infection | |
| EP1368050B1 (en) | Virus derived antimicrobial peptides | |
| CN110563814B (zh) | 具有免疫调节作用的多肽及其应用 | |
| US20090028820A1 (en) | Antiviral Agent | |
| CN112641929B (zh) | 美洲大蠊宿主防御肽的抗病毒应用 | |
| US20240018207A1 (en) | Interferon tau fc-fusion proteins and methods for treating coronavirus infections | |
| JP4188897B2 (ja) | ウィルス感染・増殖抑制剤 | |
| AU2020204461A1 (en) | A method of in vivo treatment | |
| NZ736735B2 (en) | A method of in vivo treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Lapsed because of non-payment of the annual fee |
Effective date: 20230501 |